|
|
|
MIRA INFORM REPORT
|
Report No. : |
511187 |
|
Report Date : |
29.05.2018 |
IDENTIFICATION DETAILS
|
Name : |
ABBOTT INDIA LIMITED |
|
|
|
|
Formerly Known
As : |
KNOLL PHARMACEUTICALS LIMITED (w.e.f 1995) KNOLL PHARCEUTICALS LIMITED |
|
|
|
|
Registered
Office : |
Unit No. 3-4, Corporate Park, Sion-Trombay Road, Chembur, Mumbai - 400071, Maharashtra |
|
Tel. No.: |
91-22-67978888 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2018 |
|
|
|
|
Date of
Incorporation : |
22.08.1944 |
|
|
|
|
Com. Reg. No.: |
11-007330 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
INR 212.500 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
L24239MH1944PLC007330 |
|
|
|
|
IEC No.: [Import-Export Code No.] |
Not Applicable [As informed by the management that firm does
not have export and import] |
|
|
|
|
TIN No.: |
Not Divulged |
|
|
|
|
GSTN : [Goods & Service Tax
Registration No.] |
Not Divulged |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
Not Available |
|
|
|
|
PAN No.: [Permanent Account No.] |
Not Divulged |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The Company’s Shares are Listed on
the Stock Exchanges. |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical Products.
[Registered Activity] |
|
|
|
|
No. of Employees
: [As On
31.03.2017] |
3083 [Approximately] |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A++ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
Maximum Credit Limit : |
USD 48360000 |
|
|
|
|
Status : |
Excellent |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject was incorporated in the year 1944. It is a manufacturer of
pharmaceutical products. It is a step down subsidiary of Abbott Laboratories,
USA, which is at 135th position in the Fortune 500 Company’s list. As per the financial record of 2018, the company has gained a decent
growth of 12.54% in its revenue as compared to the previous year’s revenue
and has achieved fair net profit margin of 12.13%. The company possesses strong financial position marked by robust net
worth base, comfortable liquidity level and zero debt balance sheet profile. Rating takes into consideration the company’s favourable earnings per
share of INR 188.81 as against its face value of INR 10. Rating also takes into consideration the strong financial and
managerial support that the company receives from its parent company. The company has its share price trading at around INR 6699.95 on BSE
as on May 24, 2018 as against the Face Value (FV) of INR 10. Business is active. Payment seems to be regular. In view of aforesaid, the company can be considered for business
dealings at usual trade terms and condition. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
EXTERNAL AGENCY RATING
NOT AVAILABLE
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2018.
BIFR (Board for Industrial & Financial Reconstruction) LISTING
STATUS
Subject’s name is not listed as a Sick Unit in
the publicly available BIFR (Board for Industrial & Financial
Reconstruction) list as of 29.05.2018.
IBBI (Insolvency and Bankruptcy Board of India) LISTING STATUS
Subject’s name is not listed in the publicly
available IBBI (Insolvency and Bankruptcy Board of India) list as of report
date.
INFORMATION DECLINED BY
|
Name : |
Dr. Nivedita Madkaikur |
|
Designation : |
Clinical Project Manager |
|
Contact No.: |
91-22-38162434 |
|
Date : |
24.05.2018 |
|
|
|
|
Name : |
Ms. Sneha Nair |
|
Designation : |
Head of Chief Clinical Project |
|
Contact No.: |
91-9970780488 |
|
Date : |
24.05.2018 |
MANAGEMENT NON-COOPERATIVE [TEL. NO.: 91-22-67978888]
LOCATIONS
|
Registered Office : |
Unit No. 3, Corporate Park, Sion Trombay Road, Chembur, Mumbai - 400071, Maharashtra, India |
|
Tel. No.: |
91-22-67978888 |
|
Mobile No.: |
91-9970780488 [Dr. Nivedita Madkaikur] |
|
Fax No.: |
91-22-67978920 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Corporate Office : |
16th Floor, Godrej BKC, Plot – C, “G” Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India |
|
Tel. No.: |
91-22-38162000 |
|
Fax No.: |
91-22-38162400 |
|
|
|
|
Factory : |
L-18, Verna Industrial Area, Verna Salcette, Goa – 403722, India |
|
Tel. No.: |
91-832-783415 |
DIRECTORS
AS ON: 31.03.2018
|
Name : |
Mr. Ambati Venu |
|
Designation : |
Managing Director |
|
Address : |
House No - E-148, Richmond Park, Dlf-4 Gurugram-122001, Haryana, India
|
|
Date of Appointment : |
29.09.2016 |
|
DIN No.: |
07614849 |
|
|
|
|
Name : |
Mr. Rajendra Ambalal Shah |
|
Designation : |
Director |
|
Address : |
Panorama, 2nd Floor 203, Walkeshwar Road Mumbai- 400006, Maharashtra,
India |
|
Date of Appointment : |
21.02.1983 |
|
DIN No.: |
00009851 |
|
|
|
|
Name : |
Munir Shaikh |
|
Designation : |
Director |
|
Address : |
1A, Wilby Road Na 275982 Sg |
|
Date of Appointment : |
02.03.2001 |
|
DIN No.: |
00096273 |
|
|
|
|
Name : |
Mr. Krishna Mohan Sahni |
|
Designation : |
Director |
|
Address : |
38, Jasola Vihar, Pocket 2, New Delhi -110025, India |
|
Date of Appointment : |
29.10.2014 |
|
DIN No.: |
02103128 |
|
|
|
|
Name : |
Kaiyomarz Minoo Marfatia |
|
Designation : |
Director |
|
Address : |
4, Ratan Mansion Forjett St. Mumbai 400036, Maharashtra, India |
|
Date of Appointment : |
01.03.2011 |
|
DIN No.: |
03449627 |
|
|
|
|
Name : |
Mrs. Anisha Motwani |
|
Designation : |
Additional Director |
|
Address : |
Block No. 8, House No. 24, South Patel Nagar, Delhi - 110008, India |
|
Date of Appointment : |
25.04.2018 |
|
DIN No.: |
06943493 |
|
|
|
|
Name : |
Mr. Rajiv Balkrishna Sonalker |
|
Designation : |
Whole-time Director |
|
Address : |
1703A, Valencia, Hiranandani Gardens, Powai, Mumbai -400076 , Maharashtra, India |
|
Date of Appointment : |
08.08.2017 |
|
PAN No.: |
AGTPS1950J |
|
DIN No.: |
07900178 |
KEY EXECUTIVES
|
Name : |
Mr. Rajiv Balkrishna Sonalker |
|
Designation : |
Chief Finance Officer |
|
Address : |
1703A, Valencia, Hiranandani Gardens, Powai, Mumbai -400076 ,
Maharashtra, India |
|
Date of Appointment : |
28.05.2014 |
|
PAN No.: |
AGTPS1950J |
|
|
|
|
Name : |
Mr. Krupa Ketan Anandpara |
|
Designation : |
Company Secretary |
|
Address : |
A/301, Leena Enclave, S. V. Road Fateh Baug, Borivli (West) Mumbai-
400039 , Maharashtra, India |
|
Date of Appointment : |
28.03.2006 |
|
PAN No.: |
AEOPA0336H |
|
|
|
|
Name : |
Dr. Nivedita Madkaikur |
|
Designation : |
Clinical Project Manager |
|
|
|
|
Name : |
Ms. Sneha Nair |
|
Designation : |
Head of Chief Clinical Project |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON: 31.03.2018
|
Category of
shareholder |
No. of fully paid up
equity shares held |
Shareholding as a % of
total no. of shares (calculated as per SCRR, 1957)As a % |
|
(A) Promoter & Promoter Group |
15934048 |
74.99 |
|
(B) Public |
5315254 |
25.01 |
|
|
|
|
|
Total |
21249302 |
100.00 |
Statement showing shareholding
pattern of the Promoter and Promoter Group
|
Category of shareholder |
No. of fully paid up equity shares held |
Shareholding as a % of total no. of shares
(calculated as per SCRR, 1957)As a % of (A+B+C2) |
|
|
A1) Indian |
0.00 |
||
|
A2) Foreign |
0.00 |
||
|
Any Other
(specify) |
15934048 |
74.99 |
|
|
ABBOTT CAPITAL
INDIA LIMITED |
10719097 |
50.44 |
|
|
ABBOTT HEALTHCARE
PRODUCTS LIMITED |
3744951 |
17.62 |
|
|
BRITISH COLLOIDS
LIMITED |
1470000 |
6.92 |
|
|
Sub Total A2 |
15934048 |
74.99 |
|
|
A=A1+A2 |
15934048 |
74.99 |
Statement showing
shareholding pattern of the Public shareholder
|
Category & Name of the Shareholders |
No. of fully paid up equity shares held |
Shareholding % calculated as per SCRR, 1957
As a % of (A+B+C2) |
|
|
|||
|
|||
|
|||
|
B1) Institutions |
0 |
0.00 |
|
|
Mutual Funds/ |
1130435 |
5.32 |
|
|
RELIANCE CAPITAL TRUSTEE
COMPANY LIMITED A/C RELIANCE GROWTH FUND |
589881 |
2.78 |
|
|
FRANKLIN TEMPLETON
MUTUAL FUND A/C FRANKLIN INDIA HIGH GROWTH COMPANIES FUND |
409962 |
1.93 |
|
|
Alternate
Investment Funds |
104087 |
0.49 |
|
|
Foreign Portfolio
Investors |
598494 |
2.82 |
|
|
Financial
Institutions/ Banks |
106518 |
0.50 |
|
|
Insurance
Companies |
39631 |
0.19 |
|
|
Any Other
(specify) |
26442 |
0.12 |
|
|
Overseas Corporate
Bodies |
26442 |
0.12 |
|
|
Sub Total B1 |
2005607 |
9.44 |
|
|
B2) Central Government/
State Government(s)/ President of India |
0 |
0.00 |
|
|
B3)
Non-Institutions |
0 |
0.00 |
|
|
Individual share
capital upto INR 0.200 Million |
2885416 |
13.58 |
|
|
Individual share
capital in excess of INR 0.200 Million |
46642 |
0.22 |
|
|
NBFCs registered
with RBI |
1628 |
0.01 |
|
|
Any Other
(specify) |
375961 |
1.77 |
|
|
Trusts |
465 |
0.00 |
|
|
Non-Resident
Indian (NRI) |
82350 |
0.39 |
|
|
Clearing Members |
3811 |
0.02 |
|
|
Overseas Corporate
Bodies |
471 |
0.00 |
|
|
Bodies Corporate |
136691 |
0.64 |
|
|
IEPF |
51809 |
0.24 |
|
|
Unclaimed or
Suspense or Escrow Account |
24671 |
0.12 |
|
|
Director or
Director's Relatives |
6874 |
0.03 |
|
|
HUF |
68819 |
0.32 |
|
|
Sub Total B3 |
3309647 |
15.58 |
|
|
B=B1+B2+B3 |
5315254 |
25.01 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Products.
[Registered Activity] |
|
|
|
|
Brand Names : |
Not Available |
|
|
|
|
Agencies Held : |
Not Available |
|
|
|
|
Exports : |
Not Divulged |
|
|
|
|
Imports : |
Not Divulged |
|
|
|
|
Terms : |
|
|
Selling : |
Not Divulged |
|
|
|
|
Purchasing : |
Not Divulged |
PRODUCTION STATUS: NOT AVAILABLE
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||
|
|
|
||||||||||||||
|
Customers : |
|
||||||||||||||
|
|
|
||||||||||||||
|
No. of Employees : [As On 31.03.2017] |
3083 [Approximately] |
||||||||||||||
|
|
|
||||||||||||||
|
Bankers : |
· Standard Chartered Bank · BNP Paribas · Hongkong and Shanghai Banking Corporation · HDFC Bank · ICICI Bank |
||||||||||||||
|
|
|
||||||||||||||
|
Facilities : |
-- |
|
|
|
|
Statutory Auditors : [As On 31.03.2017] |
|
|
Name : |
SRBC and Company Chartered Accountants |
|
|
|
|
Internal Auditor: [As On 31.03.2017] |
|
|
Name : |
KPMG Chartered Accountants |
|
|
|
|
Memberships : |
Not Available |
|
|
|
|
Collaborators : |
Not Available |
|
|
|
|
Ultimate Holding
Company: [As On 31.03.2017] |
Abbott Laboratories, USA |
|
|
|
|
Holding Company : [As On 31.03.2017] |
Abbott Capital India Ltd., UK |
|
|
|
|
Fellow subsidiaries : [As On 31.03.2017] |
· British Colloids Limited, UK · Abbott Healthcare Products Limited, UK · Abbott Healthcare Private Limited, India · Abbott International LLC, USA · Abbott Laboratories S.A, Switzerland · Abbott Products Operations AG., Switzerland · Abbott Manufacturing Pte Limited, Singapore · Abbott Lab (Malaysia) Sdn. Bhd · Abbott Laboratories, De Mexico · Abbott Laboratories S A, Dubai |
CAPITAL STRUCTURE
AS ON 31.03.2018
Authorised Capital : Not Available
Issued, Subscribed & Paid-up Capital : INR 212.500 Million
AS ON: 31.03.2017
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
27500000 |
Equity Shares |
INR 10/- each |
INR 275.000 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
21249302 |
Equity Shares |
INR 10/- each |
INR 212.493 Million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in INR Million]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
212.500 |
212.493 |
212.493 |
|
(b) Reserves & Surplus |
16715.100 |
13656.947 |
11743.497 |
|
(c) Money received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share
Application money pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
16927.600 |
13869.440 |
11955.990 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) Long-term borrowings |
0.000 |
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
0.000 |
0.000 |
0.000 |
|
(c)
Other long term liabilities |
0.000 |
0.000 |
0.000 |
|
(d)
long-term provisions |
553.500 |
472.195 |
386.354 |
|
Total
Non-current Liabilities (3) |
553.500 |
472.195 |
386.354 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a)
Short term borrowings |
0.000 |
0.000 |
0.000 |
|
(b)
Trade payables |
4806.300 |
4746.934 |
2301.405 |
|
(c)
Other current liabilities |
1099.800 |
845.585 |
599.105 |
|
(d)
Short-term provisions |
774.700 |
703.928 |
922.225 |
|
Total
Current Liabilities (4) |
6680.800 |
6296.447 |
3822.735 |
|
|
|
|
|
|
TOTAL |
24161.900 |
20638.082 |
16165.079 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a)
Fixed Assets |
|
|
|
|
(i)
Tangible assets |
785.800 |
1076.506 |
1058.947 |
|
(ii)
Intangible Assets |
28.000 |
19.466 |
25.619 |
|
(iii)
Capital work-in-progress |
21.700 |
51.446 |
19.080 |
|
(iv) Intangible assets under development |
0.000 |
11.348 |
9.262 |
|
(b) Non-current
Investments |
0.000 |
0.000 |
0.000 |
|
(c) Deferred tax assets
(net) |
146.000 |
123.805 |
93.869 |
|
(d) Long-term Loan
and Advances |
377.300 |
270.500 |
194.605 |
|
(e)
Other Non-current assets |
148.400 |
179.493 |
257.377 |
|
Total
Non-Current Assets |
1507.200 |
1732.564 |
1658.759 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a)
Current investments |
0.000 |
0.000 |
0.000 |
|
(b)
Inventories |
5853.300 |
5006.312 |
3701.029 |
|
(c)
Trade receivables |
2634.400 |
1742.238 |
1450.202 |
|
(d)
Cash and cash equivalents |
10313.500 |
10909.204 |
8394.219 |
|
(e)
Short-term loans and advances |
2957.600 |
535.634 |
427.422 |
|
(f)
Other current assets |
895.900 |
712.130 |
533.448 |
|
Total
Current Assets |
22654.700 |
18905.518 |
14506.320 |
|
|
|
|
|
|
TOTAL |
24161.900 |
20638.082 |
16165.079 |
PROFIT
& LOSS ACCOUNT
|
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
|
|
SALES |
|
|
|
|
|
|
|
Revenue from Operations |
33071.200 |
29386.912 |
26456.417 |
|
|
|
Other Income |
1169.900 |
576.428 |
505.869 |
|
|
|
TOTAL |
34241.100 |
29963.340 |
26962.286 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of Materials Consumed |
2957.200 |
3159.427 |
3127.773 |
|
|
|
Purchases of Stock-in-Trade |
17112.200 |
14975.657 |
11643.841 |
|
|
|
Changes in inventories of finished goods, work-in-progress
and Stock-in-Trade |
(1022.000) |
(1014.431) |
148.650 |
|
|
|
Employees benefits expense |
3936.900 |
3452.704 |
3410.874 |
|
|
|
Excise duty on sales |
86.200 |
361.331 |
311.374 |
|
|
|
Other expenses |
4755.700 |
4479.062 |
4170.002 |
|
|
|
TOTAL |
27826.200 |
25413.750 |
22812.514 |
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION |
6414.900 |
4549.590 |
4149.772 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
38.200 |
20.365 |
25.249 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION |
6376.700 |
4529.225 |
4124.523 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
161.900 |
164.308 |
144.408 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
6214.800 |
4364.917 |
3980.115 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
2202.600 |
1598.429 |
1427.615 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
4012.200 |
2766.488 |
2552.500 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (INR) |
188.81 |
130.19 |
120.12 |
|
CURRENT MATURITIES OF LONG TERM DEBT DETAILS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Current Maturities of Long term debt |
NA |
NA |
NA |
|
|
|
|
|
|
Cash generated from operations |
NA |
NA |
NA |
|
|
|
|
|
|
Net Cash flow from (used in) Operating Activities |
NA |
3072.193 |
2486.764 |
KEY
RATIOS
EFFICIENCY RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Average Collection Days (Sundry
Debtors / Income * 365 Days) |
29.08 |
21.64 |
20.01 |
|
|
|
|
|
|
Account Receivables Turnover (Income / Sundry Debtors) |
12.55 |
16.87 |
18.24 |
|
|
|
|
|
|
Average Payment Days (Sundry Creditors / Purchases * 365 Days) |
87.41 |
95.54 |
56.87 |
|
|
|
|
|
|
Inventory Turnover (Operating Income / Inventories) |
1.10 |
0.91 |
1.12 |
|
|
|
|
|
|
Asset Turnover (Operating Income / Net Fixed Assets) |
7.68 |
3.93 |
3.73 |
LEVERAGE RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Debt Ratio ((Borrowing
+ Current Liabilities) / Total Assets) |
0.28 |
0.31 |
0.24 |
|
|
|
|
|
|
Debt Equity Ratio (Total Liability / Networth) |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
Current Liabilities to Networth (Current Liabilities / Net Worth) |
0.39 |
0.45 |
0.32 |
|
|
|
|
|
|
Fixed Assets to Networth (Net Fixed Assets / Networth) |
0.05 |
0.08 |
0.09 |
|
|
|
|
|
|
Interest Coverage Ratio (PBIT / Financial Charges) |
167.93 |
223.40 |
164.35 |
PROFITABILITY RATIOS
|
PARTICULARS |
|
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Net Profit Margin ((PAT / Sales) * 100) |
% |
12.13 |
9.41 |
9.65 |
|
|
|
|
|
|
|
Return on Total Assets ((PAT / Total Assets) * 100) |
% |
16.61 |
13.40 |
15.79 |
|
|
|
|
|
|
|
Return on Investment (ROI) ((PAT / Networth) * 100) |
% |
23.70 |
19.95 |
21.35 |
SOLVENCY RATIOS
|
PARTICULARS |
31.03.2018 |
31.03.2017 |
31.03.2016 |
|
Current Ratio (Current
Assets / Current Liabilities) |
3.39 |
3.00 |
3.79 |
|
|
|
|
|
|
Quick Ratio ((Current Assets – Inventories) / Current
Liabilities) |
2.51 |
2.21 |
2.83 |
|
|
|
|
|
|
G-Score Ratio Financial (Networth / Total Assets) |
0.70 |
0.67 |
0.74 |
|
|
|
|
|
|
G-Score Ratio Debt (Debts / Equity Capital) |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
G-Score Ratio Liquidity (Total Current Assets / Total Current Liabilities) |
3.39 |
3.00 |
3.79 |
Total
Liability = Short-term Debt + Long-term Debt + Current Maturities of Long-term
debts
STOCK
PRICES
|
Face Value |
INR 10/- |
|
|
|
|
Market Value |
INR 6699.95/- |
FINANCIAL ANALYSIS
[all figures are
in INR Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR
In Million |
INR
In Million |
INR
In Million |
|
Share Capital |
212.493 |
212.493 |
212.500 |
|
Reserves & Surplus |
11743.497 |
13656.947 |
16715.100 |
|
Money received against share
warrants |
0.000 |
0.000 |
0.000 |
|
Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Net
worth |
11955.990 |
13869.440 |
16927.600 |
|
|
|
|
|
|
long-term borrowings |
0.000 |
0.000 |
0.000 |
|
Short term borrowings |
0.000 |
0.000 |
0.000 |
|
Total
borrowings |
0.000 |
0.000 |
0.000 |
|
Debt/Equity
ratio |
0.000 |
0.000 |
0.000 |
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR
In Million |
INR
In Million |
INR
In Million |
|
Sales |
26456.417 |
29386.912 |
33071.200 |
|
|
|
11.077 |
12.537 |
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2016 |
31.03.2017 |
31.03.2018 |
|
|
INR
In Million |
INR
In Million |
INR
In Million |
|
Sales |
26456.417 |
29386.912 |
33071.200 |
|
Profit |
2552.500 |
2766.488 |
4012.200 |
|
|
9.65% |
9.41% |
12.13% |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
No |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
No |
|
8 |
Designation of contact person |
No |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
Yes |
|
12 |
Voter Id Card No. of Proprietor / Partners |
Yes |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
No |
|
16 |
No. of employees |
No |
|
17 |
Details of sister concerns |
Yes |
|
18 |
Major suppliers |
No |
|
19 |
Major customers |
No |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
No |
|
22 |
Conduct of the banking account |
-- |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last three years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
No |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
No |
|
32 |
Litigations that the firm/promoter
involved in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
No |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
INDEX OF CHARGES: NO
CHARGES EXISTS FOR COMPANY
COMPANY INFORMATION
[AS ON 31.03.2017]
The company is a public limited company domiciled and incorporated in india under the provisions of the companies Act, 1913. The company is listed and traded on the Bombay stock exchange and also traded on the national stock exchange. The registered office of the company is 3-4, Corporate Park Sion-Trombay Road, Mumbai - 400071, India.
The company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
FIXED ASSETS
Tangible Assets
· Leasehold Land
· Leasehold improvement
· Buildings
· Plant and Equipment
· Furniture and Fixture
· Office Equipment
· Vehicles
Intangible Assets
· Software
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
INR |
|
US Dollar |
1 |
INR 67.44 |
|
UK Pound |
1 |
INR 89.89 |
|
Euro |
1 |
INR 79.00 |
INFORMATION DETAILS
|
Information
Gathered by : |
PNM |
|
|
|
|
Analysis Done by
: |
NYT |
|
|
|
|
Report Prepared
by : |
ARC |
SCORE FACTORS
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.